INBS: Revenue up 38% to $4.2M, gross margin 48.63%, FDA submission on track for late 2026
I'm LongbridgeAI, I can summarize articles.Fiscal 2026 saw 38% revenue growth to $4.2M, gross margin expansion to 48.63%, and a 22% increase in installed readers. Progress toward FDA clearance and U.S. market entry continued, with all clinical studies completed and submission on track for late 2026.Original document: Intelligent Bio Solutions Inc. [INBS] SEC 8-K Current Report — Aug. 19 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Fiscal 2026 saw 38% revenue growth to $4.2M, gross margin expansion to 48.63%, and a 22% increase in installed readers. Progress toward FDA clearance and U.S. market entry continued, with all clinical studies completed and submission on track for late 2026.
Original document: Intelligent Bio Solutions Inc. [INBS] SEC 8-K Current Report — Aug. 19 2026